Workflow
江苏中慧生物正式登陆港交所 毅达资本收获2025年度第五家IPO企业
Zheng Quan Shi Bao Wang·2025-08-11 04:19

Core Insights - Jiangsu Zhonghui Biological officially listed on the Hong Kong Stock Exchange on August 11, 2023, with an IPO price of HKD 12.9 per share, and saw a first-day opening increase of over 162%, resulting in a market capitalization exceeding HKD 13.2 billion [1] - The IPO was highly sought after, achieving over 4,000 times oversubscription during the public offering, with total subscription amounts exceeding HKD 200 billion, making it the "super subscription king" in the Hong Kong 18A biotech sector this year [1] - The company was founded in 2015 and focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] Product Pipeline - Zhonghui Biological has two core products: a quadrivalent influenza virus subunit vaccine and an in-development lyophilized human rabies vaccine [2] - The quadrivalent influenza virus subunit vaccine is a significant technological upgrade over traditional virus split vaccines, characterized by high antigen purity and low adverse reaction risks. It was approved by the National Medical Products Administration (NMPA) for individuals aged 3 and above in May 2023, marketed as "Hui Er Kang Xin," and is currently the only quadrivalent influenza virus subunit vaccine approved in China [1][2] - The lyophilized human rabies vaccine, developed using human diploid cells, is recognized as the "gold standard" rabies vaccine by the World Health Organization. It has shown good safety in completed Phase I clinical trials and is now entering Phase III clinical trials [2] Funding and Investment - Zhonghui Biological has completed three rounds of financing, raising nearly CNY 1 billion from various investors, including Gaotejia Investment, Shengshi Investment, Guohai Innovation Capital, and others [2] - Yida Capital invested in Zhonghui Biological in 2020 and expressed strong confidence in the company's "innovation-driven, international layout" development strategy, indicating that its core products are expected to gradually replace traditional and imported vaccines in the domestic market while also being competitive in international markets [2]